Bicycle Therapeutics (BCYC) Interest Expenses (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Interest Expenses came in at $3.6 million in Q2 2026, up 35.5% YoY from $2.7 million in Q2 2025, and little changed on a QoQ basis from $3.6 million in Q1 2026.
Bicycle Therapeutics (BCYC) Interest Expenses (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Interest Expenses data on file, last reported at $3.6 million in Q2 2026.
- Quarterly Interest Expenses rose 35.5% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 35.5% YoY) and the FY2025 annual result came in at $126.8 million, up 27.18% from the prior year.
- Interest Expenses held at $3.6 million in Q2 2026, from $3.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $130.4 million in Q1 2022 to a low of -$1.4 million in Q4 2024.
- A 5-year average of $25.8 million and a median of $11.1 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 24887.55% — and 2024, when it slumped 489.71%.
- Tracing BCYC's Interest Expenses over 5 years: stood at $636000.0 in 2022, then plunged by 138.21% to -$243000.0 in 2023, then tumbled by 489.71% to -$1.4 million in 2024, then soared by 361.76% to $3.8 million in 2025, then slipped by 4.05% to $3.6 million in 2026.
- The last three Interest Expenses figures came in at $3.6 million (Q2 2026), $3.6 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Jun 30, 2026 | 3.60 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 5.81 Mn |
| Dec 31, 2025 | 5.81 Mn |
| Sep 30, 2025 | 3.08 Mn |
| Sep 30, 2025 | 3.08 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 43.33 Mn |
| Sep 30, 2024 | 43.33 Mn |
| Jun 30, 2024 | 30.75 Mn |
| Jun 30, 2024 | 30.75 Mn |
| Mar 31, 2024 | 61.56 Mn |
| Mar 31, 2024 | 61.56 Mn |